Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 9/20 | 0.64 |
| ▸ | CDK1 | P06493 | 8/20 | 0.64 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | F3 | P13726 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15472007 | 0.82 | MAPKAPK2 (0.68) | MAPKAPK2CDK1PRKD1PRKD3PRKD2 | |
| SCHEMBL6317783 | 0.78 | MAPKAPK2 (1.00) | MAPKAPK2CDK1PRKD1KDM4E | |
| SCHEMBL6652104 | 0.78 | CDK1 (0.58) | MAPKAPK2CDK1PRKD1PRKD3PRKD2 | |
| SCHEMBL6312376 | 0.77 | CDK1 (0.59) | MAPKAPK2CDK1PRKD1PRKD3PRKD2 | |
| SCHEMBL9920620 | 0.73 | MAPKAPK2 (0.71) | MAPKAPK2CDK1PRKD1 | |
| SCHEMBL19696358 | 0.72 | CDK1 (0.65) | MAPKAPK2CDK1PRKD1 | |
| SCHEMBL6313843 | 0.71 | PIM1 (0.36) | MAPKAPK2CDK1PRKD1PRKD3PRKD2 | |
| SCHEMBL6311332 | 0.71 | MAPT (0.47) | KDM4EPIM1PIM2 | |
| SCHEMBL6312417 | 0.69 | CDK1 (0.37) | MAPKAPK2CDK1PRKD1PRKD3PRKD2 | |
| SCHEMBL6312999 | 0.69 | MAPT (0.57) | PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250765-A1 | Diazepinones as antiviral agents | CHO HIDETSURA | 2005-11-10 | — | — | US | claimed |
| US-20040116410-A1 | Diazepinones as antiviral agents | CHO HIDETSURA (JP) | 2004-06-17 | — | — | US | claimed |
| WO-2002014324-A2 | DIAZEPINONES AS ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-02-21 | — | — | WO | claimed |
| US-20050250765-A1 | Diazepinones as antiviral agents | CHO HIDETSURA | 2005-11-10 | — | — | US | disclosed |
| US-20040116410-A1 | Diazepinones as antiviral agents | CHO HIDETSURA (JP) | 2004-06-17 | — | — | US | disclosed |
| WO-2002014324-A2 | DIAZEPINONES AS ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250765-A1 | Diazepinones as antiviral agents | ZC3HAV1, ECI1, ZC3HAV1L | MAPKAPK2 3952/4885CDK1 274/4885PRKD1 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.